← Torna allo Screener

Ligand Pharmaceuticals

LGND Mid Cap

Healthcare · Biotechnology

Aggiornato: May 2, 2026, 22:05 UTC

194,01 €
-0.88% oggi
52W: 84,36 € – 211,02 €
52W Low: 84,36 € Posizione: 86.6% 52W High: 211,02 €

Metriche Chiave

P/E Ratio
37.04x
Rapporto P/E
Forward P/E
19.87x
P/E Forward
P/S Ratio
10.29x
Prezzo/Vendite
EV/EBITDA
52.53x
Valore Impresa/EBITDA
Rendimento Dividendi
Rendimento annuale da dividendi
Cap. di Mercato
2,4 Mrd. €
Capitalizzazione di Mercato
Crescita Ricavi
39.4%
Crescita Ricavi Anno su Anno
Margine di Profitto
46.42%
Margine Netto
ROE
13.47%
Return on Equity
Beta
1
Sensibilità al mercato
Interesse Corto
8.49%
% del flottante in vendita allo scoperto
Volume Medio
220,750
Volume Medio Giornaliero

Analisi della Valutazione

Segnale
Sopravvalutata
vs. P/E medio S&P 500 (24,7x)
Consenso degli Analisti
Acquisto Forte
10 analisti
Prezzo Obiettivo Medio
228,61 €
+17.83% potenziale
Range Obiettivo
187,67 € – 281,50 €

Informazioni sull'Azienda

Settore: Healthcare Industria: Biotechnology Paese: United States Dipendenti: 47 Borsa: NGM

Ligand Pharmaceuticals Stock at a Glance

Ligand Pharmaceuticals (LGND) is currently trading at 194,01 € with a market capitalization of 2,4 Mrd. €. The trailing P/E ratio stands at 37.04x, with a forward P/E of 19.87x. The 52-week range spans from 84,36 € to 211,02 €; the current price is 8.1% below the yearly high. Year-over-year revenue growth stands at +39.4%. The net profit margin stands at 46.42%.

💰 Dividendo

Ligand Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Raccomandazioni degli Analisti

10 analysts rate Ligand Pharmaceuticals (LGND) on consensus: Acquisto Forte. The average price target is 228,61 €, implying +17.83% from the current price. Analyst price targets range from 187,67 € to 281,50 €.

Tesi di Investimento: Punti di Forza e Debolezze

Punti di Forza
  • Strong revenue growth of 39.4% YoY
  • Profitable with 46.42% net margin
  • High gross margin of 64.29% — indicates pricing power
  • Analyst consensus: Strong Buy
  • Solid balance sheet with low debt (D/E 44.39)
  • Positive free cash flow
Debolezze
  • Currently flagged as overvalued

Panoramica Tecnica

MM 50 Giorni
179,43 €
+8.12% vs. prezzo
MM 200 Giorni
159,58 €
+21.58% vs. prezzo
Sotto Massimo 52S
−8.1%
211,02 €
Sopra Minimo 52S
+130%
84,36 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profilo di Rischio

Rischio di Mercato (Beta)
1 · Market-like
Moves less than the overall market
Short Interest
8.49% · Elevated
% del flottante in vendita allo scoperto
Debt-to-Equity
44.39 · Low
Debito totale / patrimonio

The data points to market-like volatility, elevated short interest (8.49%).

Dati di Trading

50-Day MA: 179,43 €
200-Day MA: 159,58 €
Volume: 228,440
Volume Medio: 220,750
Ratio Corto: 5.62
Rapporto P/B: 4.42x
Debito/Patrimonio: 44.39x
Flusso di Cassa Libero: 74 M €

Where can I buy Ligand Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top